MD3652215T2 - Moleculă polipeptidică îmbunătăţită cu specificitate duală - Google Patents

Moleculă polipeptidică îmbunătăţită cu specificitate duală

Info

Publication number
MD3652215T2
MD3652215T2 MDE20200533T MDE20200533T MD3652215T2 MD 3652215 T2 MD3652215 T2 MD 3652215T2 MD E20200533 T MDE20200533 T MD E20200533T MD E20200533 T MDE20200533 T MD E20200533T MD 3652215 T2 MD3652215 T2 MD 3652215T2
Authority
MD
Moldova
Prior art keywords
polypeptide molecule
dual specificity
improved dual
specificity polypeptide
region derived
Prior art date
Application number
MDE20200533T
Other languages
English (en)
Inventor
Martin Hofmann
Felix Unverdorben
Sebastian Bunk
Dominik Maurer
Original Assignee
Immatics Biotechnologies Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from DE102017115966.5A external-priority patent/DE102017115966A1/de
Application filed by Immatics Biotechnologies Gmbh filed Critical Immatics Biotechnologies Gmbh
Publication of MD3652215T2 publication Critical patent/MD3652215T2/ro

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2809—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against the T-cell receptor (TcR)-CD3 complex
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/08—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses
    • C07K16/10—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses from RNA viruses
    • C07K16/1036—Retroviridae, e.g. leukemia viruses
    • C07K16/1045—Lentiviridae, e.g. HIV, FIV, SIV
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2833—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against MHC-molecules, e.g. HLA-molecules
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/46—Hybrid immunoglobulins
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/46—Hybrid immunoglobulins
    • C07K16/468—Immunoglobulins having two or more different antigen binding sites, e.g. multifunctional antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/32—Immunoglobulins specific features characterized by aspects of specificity or valency specific for a neo-epitope on a complex, e.g. antibody-antigen or ligand-receptor
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/626—Diabody or triabody
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Virology (AREA)
  • Hematology (AREA)
  • AIDS & HIV (AREA)
  • Oncology (AREA)
  • Cell Biology (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)

Abstract

Prezenta invenţie se referă la o moleculă de polipeptidă bispecifică care cuprinde un prim lanţ polipeptidic şi un al doilea lanţ polipeptidic care asigură o regiune de legare derivată de la un receptor de celule T (TCR) fiind specifică pentru un epitop peptid viral asociat cu complexul de histocompatibilitate (MHC) major regiune de legare derivată dintr-un anticorp capabil să recruteze celule efectoare imune umane prin legarea specifică la un antigen de suprafaţă al respectivelor celule, precum şi metode de fabricare a moleculei de polipeptidă bispecifică şi utilizările acestora.
MDE20200533T 2017-07-14 2018-07-13 Moleculă polipeptidică îmbunătăţită cu specificitate duală MD3652215T2 (ro)

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
US201762532713P 2017-07-14 2017-07-14
DE102017115966.5A DE102017115966A1 (de) 2017-07-14 2017-07-14 Polypeptidmolekül mit verbesserter zweifacher Spezifität
DE102017119866 2017-08-30
US201862658318P 2018-04-16 2018-04-16
DE102018108995 2018-04-16
PCT/EP2018/069157 WO2019012141A1 (en) 2017-07-14 2018-07-13 IMPROVED POLYPEPTIDE MOLECULE WITH DOUBLE SPECIFICITY

Publications (1)

Publication Number Publication Date
MD3652215T2 true MD3652215T2 (ro) 2021-06-30

Family

ID=62951983

Family Applications (2)

Application Number Title Priority Date Filing Date
MDE20190844T MD3428194T2 (ro) 2017-07-14 2018-07-13 Moleculă polipeptidică cu specificitate duală îmbunătățită
MDE20200533T MD3652215T2 (ro) 2017-07-14 2018-07-13 Moleculă polipeptidică îmbunătăţită cu specificitate duală

Family Applications Before (1)

Application Number Title Priority Date Filing Date
MDE20190844T MD3428194T2 (ro) 2017-07-14 2018-07-13 Moleculă polipeptidică cu specificitate duală îmbunătățită

Country Status (28)

Country Link
US (7) US20190016802A1 (ro)
EP (3) EP3985029A1 (ro)
JP (4) JP2020530762A (ro)
KR (2) KR20200026995A (ro)
CN (2) CN110914307A (ro)
AU (2) AU2018298884A1 (ro)
BR (2) BR112020000762A2 (ro)
CA (2) CA3069842A1 (ro)
CO (2) CO2020001029A2 (ro)
CR (2) CR20200013A (ro)
CY (2) CY1124091T1 (ro)
DK (2) DK3652215T3 (ro)
ES (2) ES2871146T3 (ro)
HR (1) HRP20211744T1 (ro)
HU (2) HUE054568T2 (ro)
LT (2) LT3428194T (ro)
MA (1) MA46299B1 (ro)
MD (2) MD3428194T2 (ro)
MX (1) MX2020011744A (ro)
PE (2) PE20200614A1 (ro)
PL (2) PL3652215T3 (ro)
PT (2) PT3652215T (ro)
RS (2) RS61817B1 (ro)
SG (2) SG11202000027WA (ro)
SI (2) SI3652215T1 (ro)
TW (2) TWI762677B (ro)
WO (2) WO2019012141A1 (ro)
ZA (1) ZA202000842B (ro)

Families Citing this family (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SG11202000027WA (en) 2017-07-14 2020-02-27 Immatics Biotechnologies Gmbh Improved dual specificity polypeptide molecule
CA3100253A1 (en) 2018-05-14 2019-11-21 Immunocore Limited Bifunctional binding polypeptides
GB201904328D0 (en) 2019-03-28 2019-05-15 Immunocore Ltd Specific binding molecules
EA202193139A1 (ru) 2019-05-27 2022-03-01 Имматикс Юс, Инк. Вирусные векторы и их применение в адоптивной клеточной терапии
US20210032370A1 (en) * 2019-08-02 2021-02-04 Immatics Biotechnologies Gmbh Recruiting agent further binding an mhc molecule
DE102019121007A1 (de) 2019-08-02 2021-02-04 Immatics Biotechnologies Gmbh Antigenbindende Proteine, die spezifisch an MAGE-A binden
GB201915282D0 (en) 2019-10-22 2019-12-04 Immunocore Ltd Specific binding molecules
US20230340119A1 (en) * 2019-12-05 2023-10-26 Arbele Corp Composition of triax antibodies and method of making and using thereof
IL295891A (en) 2020-02-24 2022-10-01 Immatics Us Inc Methods for propagating t cells for the treatment of cancer and related malignancies
DE102020111571A1 (de) 2020-03-11 2021-09-16 Immatics US, Inc. Wpre-mutantenkonstrukte, zusammensetzungen und zugehörige verfahren
GB202006629D0 (en) 2020-05-05 2020-06-17 Immunocore Ltd Specific binding molecules
GB202010329D0 (en) 2020-07-06 2020-08-19 Immunocore Ltd Specific binding molecules
WO2022040631A1 (en) 2020-08-21 2022-02-24 Immatics US, Inc. Methods for isolating cd8+ selected t cells
JP2024502034A (ja) 2020-12-31 2024-01-17 イマティクス ユーエス，アイエヌシー． Ｃｄ８ポリペプチド、組成物、及びそれらの使用方法
WO2022184805A1 (en) 2021-03-03 2022-09-09 Immatics Biotechnologies Gmbh Antigen binding proteins specifically binding sars-cov-2 antigenic peptides in complex with a major histocompatibility complex protein
TW202309071A (zh) 2021-05-05 2023-03-01 德商英麥提克生物技術股份有限公司 特異性結合ｐｒａｍｅ之抗原結合蛋白
EP4113120A1 (en) 2021-06-28 2023-01-04 Immatics Biotechnologies GmbH Method of characterizing the binding characteristics between a peptide of interest and mhc molecules
US20230024554A1 (en) 2021-06-28 2023-01-26 Immatics Biotechnologies Gmbh Method of characterizing the binding characteristics between a peptide of interest and mhc molecules
CN117964777A (zh) * 2021-08-26 2024-05-03 瑅安生物医药（杭州）有限公司 一种接近天然分子的多肽融合分子
TW202332765A (zh) 2021-09-20 2023-08-16 美商英麥提克斯股份有限公司 用於ｔ細胞療法之ｔ細胞群體的單核球耗盡
US20230190807A1 (en) 2021-10-06 2023-06-22 Immatics Biotechnologies Gmbh Tcr compounds, compositions, and methods of treating
WO2023081461A1 (en) 2021-11-08 2023-05-11 Immatics US, Inc. Methods for generating cell spheroids
WO2023081925A1 (en) 2021-11-08 2023-05-11 Immatics Biotechnologies Gmbh Adoptive cell therapy combination treatment and compositions thereof
WO2023110918A1 (en) * 2021-12-14 2023-06-22 Cdr-Life Ag Dual mhc-targeting t cell engager
WO2023156663A1 (en) 2022-02-20 2023-08-24 Immunocore Limited Hiv-specific binding molecules and tcr
US20240066127A1 (en) 2022-04-28 2024-02-29 Immatics US, Inc. Il-12 polypeptides, il-15 polypeptides, il-18 polypeptides, cd8 polypeptides, compositions, and methods of using thereof
WO2023212697A1 (en) 2022-04-28 2023-11-02 Immatics US, Inc. Membrane-bound il-15, cd8 polypeptides, cells, compositions, and methods of using thereof
US20230348561A1 (en) 2022-04-28 2023-11-02 Immatics US, Inc. Dominant negative tgfbeta receptor polypeptides, cd8 polypeptides, cells, compositions, and methods of using thereof
WO2023209124A1 (en) 2022-04-29 2023-11-02 Immatics Biotechnologies Gmbh Mammalian display platform for multispecific antigen binding proteins
WO2023215825A1 (en) 2022-05-05 2023-11-09 Immatics US, Inc. Methods for improving t cell efficacy
WO2023240124A1 (en) 2022-06-07 2023-12-14 Regeneron Pharmaceuticals, Inc. Pseudotyped viral particles for targeting tcr-expressing cells
WO2024033332A1 (en) 2022-08-08 2024-02-15 Immatics Biotechnologies Gmbh Guided positional scanning method

Family Cites Families (104)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2018248A1 (en) 1989-06-07 1990-12-07 Clyde W. Shearman Monoclonal antibodies against the human alpha/beta t-cell receptor, their production and use
US6800738B1 (en) 1991-06-14 2004-10-05 Genentech, Inc. Method for making humanized antibodies
IL104570A0 (en) 1992-03-18 1993-05-13 Yeda Res & Dev Chimeric genes and cells transformed therewith
US8211422B2 (en) 1992-03-18 2012-07-03 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Chimeric receptor genes and cells transformed therewith
DK0744958T3 (da) 1994-01-31 2003-10-20 Univ Boston Polyklonale antistofbiblioteker
ES2246069T3 (es) 1997-05-02 2006-02-01 Genentech, Inc. Procedimiento de preparacion de anticuerpos multiespecificos que tienen componentes comunes y multimericos.
GB9809951D0 (en) 1998-05-08 1998-07-08 Univ Cambridge Tech Binding molecules
WO2002002781A1 (en) 2000-06-30 2002-01-10 Vlaams Interuniversitair Instituut Voor Biotechnologie Vzw Heterodimeric fusion proteins
EP2093286B1 (en) 2001-10-01 2013-02-27 Dyax Corporation Multi-chain eukaryotic display vectors and uses thereof
WO2004033685A1 (en) 2002-10-09 2004-04-22 Avidex Ltd Single chain recombinant t cell receptors
US8378074B2 (en) 2005-04-01 2013-02-19 Immunocore Limited High affinity HIV T cell receptors
US9284375B2 (en) 2005-04-15 2016-03-15 Macrogenics, Inc. Covalent diabodies and uses thereof
CA2605024C (en) 2005-04-15 2018-05-22 Macrogenics, Inc. Covalent diabodies and uses thereof
ES2564823T3 (es) 2005-05-27 2016-03-29 Ospedale San Raffaele S.R.L. Vector génico que comprende miARN
AT503861B1 (de) 2006-07-05 2008-06-15 F Star Biotech Forsch & Entw Verfahren zur manipulation von t-zell-rezeptoren
US20100105136A1 (en) 2006-10-09 2010-04-29 The General Hospital Corporation Chimeric t-cell receptors and t-cells targeting egfrviii on tumors
WO2008145139A1 (en) 2007-05-31 2008-12-04 Genmab A/S Fusion or linked proteins with extended half life
JP2011525103A (ja) 2008-01-11 2011-09-15 モルフォシス・アー・ゲー ディスプレイベクター並びにその方法及び用途
EP2258719A1 (en) * 2009-05-19 2010-12-08 Max-Delbrück-Centrum für Molekulare Medizin (MDC) Multiple target T cell receptor
WO2011041093A1 (en) 2009-10-01 2011-04-07 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Anti-vascular endothelial growth factor receptor-2 chimeric antigen receptors and use of same for the treatment of cancer
CA2777053A1 (en) 2009-10-06 2011-04-14 The Board Of Trustees Of The University Of Illinois Human single-chain t cell receptors
US20130129723A1 (en) 2009-12-29 2013-05-23 Emergent Product Development Seattle, Llc Heterodimer Binding Proteins and Uses Thereof
DK2519543T3 (en) 2009-12-29 2016-09-26 Emergent Product Dev Seattle HETERODIMER BINDING PROTEINS AND USE THEREOF
US20120294857A1 (en) 2010-01-11 2012-11-22 Trustees Of Dartmouth College Monomeric Bi-Specific Fusion Protein
GB201004551D0 (en) 2010-03-19 2010-05-05 Immatics Biotechnologies Gmbh NOvel immunotherapy against several tumors including gastrointestinal and gastric cancer
EP4303236A3 (en) 2010-11-30 2024-03-20 Chugai Seiyaku Kabushiki Kaisha Cytotoxicity-inducing therapeutic agent
EA201391159A1 (ru) 2011-02-11 2014-02-28 Мемориал Слоан-Кеттеринг Кэнсер Сентер Hla-рестриктированные пептидоспецифические антигенсвязывающие белки
US20130078250A1 (en) * 2011-08-23 2013-03-28 Oliver Ast Bispecific t cell activating antigen binding molecules
UY34317A (es) 2011-09-12 2013-02-28 Genzyme Corp Anticuerpo antireceptor de célula T (alfa)/ß
CA2887486A1 (en) 2012-11-30 2014-06-05 Roche Glycart Ag Removal of cancer cells by circulating virus-specific cytotoxic t-cells using cancer cell targeted mhc class i comprising multi-function proteins
EP3708584A1 (en) 2013-02-26 2020-09-16 Roche Glycart AG Bispecific t cell activating antigen binding molecules
RU2015140917A (ru) 2013-02-26 2017-04-03 Роше Гликарт Аг Биспецифические антигенсвязывающие молекулы, активирующие т-клетки
SI2968520T1 (sl) 2013-03-14 2022-01-31 Macrogenics, Inc. Bispecifične molekule, ki so imunoreaktivne z imunskimi efektorskimi celicami, ki izražajo aktivacijski receptor
CA2931356A1 (en) 2013-11-27 2015-06-04 Zymeworks Inc. Bispecific antigen-binding constructs targeting her2
BR122021025087B1 (pt) 2013-12-17 2023-04-04 Genentech, Inc Anticorpo anti-cd3, célula hospedeira procariótica, método de produção do anticorpo biespecífico, imunoconjugado, composição, uso do anticorpo biespecífico e kit
NZ724908A (en) 2014-03-25 2017-12-22 Merial Inc Immunological compositions containing attenuated histophilus somni
KR102523934B1 (ko) 2014-07-24 2023-04-20 2세븐티 바이오, 인코포레이티드 Bcma 키메릭 항원 수용체
EP3180359A1 (en) 2014-08-14 2017-06-21 Novartis AG Treatment of cancer using gfr alpha-4 chimeric antigen receptor
EP2985294A1 (en) 2014-08-14 2016-02-17 Deutsches Krebsforschungszentrum Recombinant antibody molecule and its use for target cell restricted T cell activation
SI3221356T1 (sl) 2014-11-20 2021-01-29 F. Hoffmann-La Roche Ag Bispecifične molekule, ki vežejo antigene in aktivirajo celice T, proti FOLR1 in CD3
GB201501017D0 (en) 2014-12-23 2015-03-04 Immatics Biotechnologies Gmbh Novel peptides and combination of peptides for use in immunotherapy against hepatocellular carcinoma (HCC) and other cancers
GB201423361D0 (en) 2014-12-30 2015-02-11 Immatics Biotechnologies Gmbh Method for the absolute Quantification of naturally processed HLA-Restricted cancer peptides
GB201504502D0 (en) 2015-03-17 2015-04-29 Immatics Biotechnologies Gmbh Novel peptides and combination of peptides for use in immunotherapy against pancreatic cancer and other cancers
WO2016154585A1 (en) 2015-03-26 2016-09-29 Charles Sentman Anti-mica antigen binding fragments, fusion molecules, cells which express and methods of using
GB201505305D0 (en) 2015-03-27 2015-05-13 Immatics Biotechnologies Gmbh Novel Peptides and combination of peptides for use in immunotherapy against various tumors
GB201505585D0 (en) 2015-03-31 2015-05-13 Immatics Biotechnologies Gmbh Novel peptides and combination of peptides and scaffolds for use in immunotherapy against renal cell carinoma (RCC) and other cancers
GB201507030D0 (en) 2015-04-24 2015-06-10 Immatics Biotechnologies Gmbh Immunotherapy against lung cancers, in particular NSCLC
GB201507719D0 (en) 2015-05-06 2015-06-17 Immatics Biotechnologies Gmbh Novel peptides and combination of peptides and scaffolds thereof for use in immunotherapy against colorectal carcinoma (CRC) and other cancers
FI3298033T4 (fi) 2015-05-18 2023-09-22 Tcr2 Therapeutics Inc Koostumuksia ja lääkinnällisiä käyttöjä fuusioproteiineja käyttävälle tcr:n uudelleenohjelmoinnille
EP3095792A1 (en) 2015-05-19 2016-11-23 Klinikum rechts der Isar der Technischen Universität München T cell receptor with specificity for myeloperoxidase peptide and uses thereof
GB201510771D0 (en) 2015-06-19 2015-08-05 Immatics Biotechnologies Gmbh Novel peptides and combination of peptides for use in immunotherapy and methods for generating scaffolds for the use against pancreatic cancer
GB201511191D0 (en) 2015-06-25 2015-08-12 Immatics Biotechnologies Gmbh T-cell epitopes for the immunotherapy of myeloma
GB201511546D0 (en) 2015-07-01 2015-08-12 Immatics Biotechnologies Gmbh Novel peptides and combination of peptides for use in immunotherapy against ovarian cancer and other cancers
GB201511792D0 (en) 2015-07-06 2015-08-19 Immatics Biotechnologies Gmbh Novel peptides and combination of peptides for use in immunotherapy against esopageal cancer and other cancers
MY189596A (en) 2015-07-15 2022-02-18 Immatics Biotechnologies Gmbh A novel peptides for use in immunotherapy against epithelial ovarian cancer and other cancers
GB201513921D0 (en) 2015-08-05 2015-09-23 Immatics Biotechnologies Gmbh Novel peptides and combination of peptides for use in immunotherapy against prostate cancer and other cancers
GB201515321D0 (en) 2015-08-28 2015-10-14 Immatics Biotechnologies Gmbh Novel peptides, combination of peptides and scaffolds for use in immunotherapeutic treatment of various cancers
US10130693B2 (en) 2015-08-28 2018-11-20 Immatics Biotechnologies Gmbh Peptides, combination of peptides and scaffolds for use in immunotherapeutic treatment of various cancers
GB201517538D0 (en) 2015-10-05 2015-11-18 Immatics Biotechnologies Gmbh Novel peptides and combination of peptides for use in immunotherapy against small cell lung cancer and other cancers
WO2017059900A1 (en) 2015-10-07 2017-04-13 Biontech Cell & Gene Therapies Gmbh Antigen receptors and uses thereof
JP6862435B2 (ja) 2015-10-09 2021-04-21 イマティクス バイオテクノロジーズ ゲーエムベーハー 抗ｗｔ１／ｈｌａ特異的抗体
DK3365364T3 (da) 2015-10-23 2024-05-06 Eureka Therapeutics Inc Kimære antistof/T-celle-receptorkonstruktioner og anvendelser deraf
GB201521746D0 (en) 2015-12-10 2016-01-27 Immatics Biotechnologies Gmbh Novel peptides and combination of peptides for use in immunotherapy against CLL and other cancers
GB201521894D0 (en) 2015-12-11 2016-01-27 Immatics Biotechnologies Gmbh Novel peptides and combination of peptides for use in immunotherapy against various cancers
GB201522592D0 (en) * 2015-12-22 2016-02-03 Immunocore Ltd T cell receptors
GB201522667D0 (en) 2015-12-22 2016-02-03 Immatics Biotechnologies Gmbh Novel peptides and combination of peptides for use in immunotherapy against breast cancer and other cancers
GB201602918D0 (en) 2016-02-19 2016-04-06 Immatics Biotechnologies Gmbh Novel peptides and combination of peptides for use in immunotherapy against NHL and other cancers
GB201603568D0 (en) 2016-03-01 2016-04-13 Immatics Biotechnologies Gmbh Efficient treatment options including peptides and combination of peptide and cell based medicaments for use in immunotherapy against urinary bladder cancer
GB201603987D0 (en) 2016-03-08 2016-04-20 Immatics Biotechnologies Gmbh Uterine cancer treatments
EP3442576A4 (en) 2016-04-15 2020-05-13 Trustees of Dartmouth College HIGH AFFINITY B7-H6 ANTIBODIES AND ANTIBODY FRAGMENTS
EP3472208B9 (en) 2016-06-17 2023-10-04 Medigene Immunotherapies GmbH T cell receptors and uses thereof
CN109643503A (zh) 2016-06-27 2019-04-16 宝洁公司 由口腔护理产品评估牙齿过敏处理的设备和方法
AU2017306432A1 (en) 2016-08-02 2019-03-21 TCR2 Therapeutics Inc. Compositions and methods for TCR reprogramming using fusion proteins
JP7012364B2 (ja) 2016-08-05 2022-02-14 国立大学法人東北大学 Ｔ細胞受容体の認識機構を用いたがん又は感染症の治療及び診断
WO2018050902A2 (en) 2016-09-15 2018-03-22 Quadrucept Bio Limited Multimers, tetramers & octamers
CN106831996B (zh) 2017-03-31 2020-05-19 北京智仁美博生物科技有限公司 具有cd3e和/或her2靶向功能的双特异性抗体及其用途
WO2018220216A1 (en) 2017-06-01 2018-12-06 Universität Stuttgart Heterodimerizing ig domains
SG11202000027WA (en) 2017-07-14 2020-02-27 Immatics Biotechnologies Gmbh Improved dual specificity polypeptide molecule
WO2019047932A1 (zh) 2017-09-08 2019-03-14 科济生物医药（上海）有限公司 基因工程化的t细胞及应用
JPWO2019151392A1 (ja) 2018-01-31 2021-02-04 国立大学法人東北大学 抗原特異的ｍｈｃ発現調節法
CA3100253A1 (en) 2018-05-14 2019-11-21 Immunocore Limited Bifunctional binding polypeptides
EA202091977A1 (ru) 2018-05-28 2021-02-09 Драгонфлай Терапьютикс, Инк. Мультиспецифические связывающие белки, которые связывают cd33, nkg2d и cd16, и способы применения
US20220275043A1 (en) 2018-07-17 2022-09-01 Massachusetts Institute Of Technology Soluble multimeric immunoglobulin-scaffold based fusion proteins and uses thereof
WO2020057610A1 (en) 2018-09-20 2020-03-26 Wuxi Biologics (Shanghai) Co., Ltd. Novel bispecific anti-ctla-4/pd-1 polypeptide complexes
GB201903767D0 (en) 2019-03-19 2019-05-01 Quadrucept Bio Ltd Multimers, tetramers & octamers
GB201906685D0 (en) 2019-05-13 2019-06-26 Ultrahuman Six Ltd Activatable protein constructs and uses thereof
MX2022000667A (es) 2019-07-15 2022-07-21 Neogene Therapeutics B V Metodo para aislar genes tcr.
DE102019121007A1 (de) 2019-08-02 2021-02-04 Immatics Biotechnologies Gmbh Antigenbindende Proteine, die spezifisch an MAGE-A binden
JP7483865B2 (ja) 2019-09-06 2024-05-15 イーライ リリー アンド カンパニー Ｔ細胞受容体の定常ドメインを含むタンパク質
CN115066274A (zh) 2019-09-25 2022-09-16 斯图加特大学 三价结合分子
JP2022549351A (ja) 2019-09-27 2022-11-24 アジェナス インコーポレイテッド ヘテロ二量体タンパク質
WO2021097365A2 (en) 2019-11-15 2021-05-20 Gritstone Oncology, Inc. Antigen-binding proteins targeting shared neoantigens
AU2020385604A1 (en) 2019-11-18 2022-06-30 BioNTech SE Prame TCR receptors and uses thereof
AU2020407591A1 (en) 2019-12-17 2022-06-23 The Johns Hopkins University Manabodies targeting tumor antigens and methods of using
CN110964122B (zh) 2019-12-24 2022-04-15 南京北恒生物科技有限公司 T细胞受体融合蛋白及其用途
EP4121079A1 (en) 2020-03-16 2023-01-25 University Of Southern California Novel antigen binding domains and synthetic antigen receptors incorporating the same
US20230130925A1 (en) 2020-03-16 2023-04-27 University Of Southern California Methods to prevent, ameliorate and treat complications from viral infections
WO2021222576A1 (en) 2020-05-01 2021-11-04 A2 Biotherapeutics, Inc. Pag1 fusion proteins and methods of making and using same
EP4165079A1 (en) 2020-06-10 2023-04-19 The University of Melbourne Hiv-1 antibodies
WO2022026358A1 (en) 2020-07-27 2022-02-03 Arizona Board Of Regents On Behalf Of The University Of Arizona Multifunctional immunoglobulin-fold polypeptides from alternative translational initiation and termination
WO2022076788A1 (en) 2020-10-09 2022-04-14 Memorial Sloan Kettering Cancer Center Compositions targeting ndc80/mhc complexes and uses thereof
WO2022083668A1 (en) 2020-10-21 2022-04-28 Nanjing Legend Biotech Co., Ltd. Use of a chimeric co-stimulatory receptor for cell therapy
US20240052009A1 (en) 2020-12-21 2024-02-15 Zymeworks Bc Inc. Stabilized tcr constructs and methods of use
CA3208717A1 (en) 2021-02-19 2022-08-25 Preet M. Chaudhary Single-chain and multi-chain synthetic antigen receptors for diverse immune cells

Also Published As

Publication number Publication date
HUE054568T2 (hu) 2021-09-28
US20230348598A1 (en) 2023-11-02
EP3428194A1 (en) 2019-01-16
JP2019023184A (ja) 2019-02-14
US20190016802A1 (en) 2019-01-17
SG11202000027WA (en) 2020-02-27
RS62544B1 (sr) 2021-12-31
TW202246330A (zh) 2022-12-01
MA46299B1 (fr) 2021-09-30
HRP20211744T1 (hr) 2022-02-04
US20190016804A1 (en) 2019-01-17
JP2020530762A (ja) 2020-10-29
ZA202000842B (en) 2022-06-29
PT3652215T (pt) 2021-05-18
TWI762677B (zh) 2022-05-01
US11905328B2 (en) 2024-02-20
US20190016801A1 (en) 2019-01-17
KR20200026994A (ko) 2020-03-11
CA3069610A1 (en) 2019-01-17
PL3652215T3 (pl) 2021-08-02
MA46299A (fr) 2019-07-31
WO2019012138A1 (en) 2019-01-17
EP3428194B1 (en) 2021-08-18
CY1124835T1 (el) 2022-11-25
JP2024023385A (ja) 2024-02-21
CY1124091T1 (el) 2022-05-27
JP2023103451A (ja) 2023-07-26
PE20200614A1 (es) 2020-03-11
US20190016803A1 (en) 2019-01-17
CA3069842A1 (en) 2019-01-17
DK3652215T3 (da) 2021-05-25
KR20200026995A (ko) 2020-03-11
EP3652215B1 (en) 2021-02-17
WO2019012141A1 (en) 2019-01-17
US20220195044A1 (en) 2022-06-23
LT3652215T (lt) 2021-05-25
CO2020001491A2 (es) 2020-02-28
SI3652215T1 (sl) 2021-08-31
CO2020001029A2 (es) 2020-02-18
CN110914307A (zh) 2020-03-24
ES2898210T3 (es) 2022-03-04
CR20200013A (es) 2020-03-11
MX2020011744A (es) 2021-01-08
ES2871146T3 (es) 2021-10-28
DK3428194T3 (da) 2021-11-15
TW201908340A (zh) 2019-03-01
EP3652215A1 (en) 2020-05-20
PE20200615A1 (es) 2020-03-11
CR20200014A (es) 2020-06-11
BR112020000762A2 (pt) 2020-07-21
EP3985029A1 (en) 2022-04-20
SG11202000025SA (en) 2020-02-27
SI3428194T1 (sl) 2021-12-31
MD3428194T2 (ro) 2022-02-28
LT3428194T (lt) 2021-12-10
AU2018298881A1 (en) 2020-01-16
CN110914308A (zh) 2020-03-24
BR112020000769A2 (pt) 2020-07-21
AU2018298884A1 (en) 2020-02-27
TWI817302B (zh) 2023-10-01
PT3428194T (pt) 2021-11-18
RS61817B1 (sr) 2021-06-30
HUE057110T2 (hu) 2022-04-28
JP6784724B2 (ja) 2020-11-11
US20220185888A1 (en) 2022-06-16
PL3428194T3 (pl) 2022-01-17

Similar Documents

Publication Publication Date Title
MD3652215T2 (ro) Moleculă polipeptidică îmbunătăţită cu specificitate duală
MX2021005022A (es) Receptores de antigenos quimericos especificos para el miembro d del grupo 5 de la clase c del receptor acoplado a proteina g (gprc5d).
MX2020004129A (es) Anticuerpos anti-cd38 y metodos de uso.
PH12020552138A1 (en) Bcma chimeric antigen receptors and uses thereof
BR112017013981A2 (pt) receptores antigênicos quiméricos com uma única cadeia específicos anti-cll1 (sccars) para imunoterapia de câncer
CO2018001405A2 (es) Receptores de antígenos quiméricos basados en anticuerpos de dominio simple
MX2019001184A (es) Anticuerpos anti-idiotípicos y métodos relacionados.
CO2018011668A2 (es) Neoantígenos y métodos de su uso
MX2020010241A (es) Composiciones de inmunoterapia celular y usos de las mismas.
CL2017001866A1 (es) Anticuerpos anti-cd3, anticuerpos anti-cd123 y anticuerpos biespecíficos que se unen específicamente a cd3 y/o cd123
AR110676A1 (es) Tratamiento del cáncer utilizando receptores de antígenos quiméricos
EA201992536A1 (ru) Tcr и пептиды
AR104718A1 (es) Receptores de antígenos quiméricos específicos de anti-gd3 para inmunoterapias contra el cáncer
BR112018067698A2 (pt) células modificadas para imunoterapia
GT201300233A (es) Receptores de celulas t similares a anticuerpos especificos para un peptido wt1 presentado por hla-a2
EA201500741A1 (ru) ВАРИАНТЫ Fc-ОБЛАСТИ IGG1 ЧЕЛОВЕКА И ИХ ПРИМЕНЕНИЕ
TR201910814T4 (tr) Kanser immünoterapisi için cd123 spesifik kimerik antijen reseptörleri.
EA201591407A1 (ru) Антитела, содержащие химерные константные домены
EA201592006A1 (ru) Новые биспецифические связывающие молекулы с противоопухолевой активностью
CR11374A (es) Proteinas humanas de union a antigenos del gm-csf
EA202190542A1 (ru) Сконструированные биспецифические белки
AR063090A1 (es) Proteinas de union al antigeno del receptor de la il-17
MX2016005687A (es) Metodos para potenciar la terapia inmunosupresora mediante administracion multiple de polipeptido de union a tcr alfa beta.
PE20201149A1 (es) Anticuerpos de union a hla-a2/wt1
AR112228A1 (es) Molécula de polipéptido con especificidad dual mejorada